Page 21 - Yi Liu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PI3K/AKT/mTOR Inhibitors for Prostate Cancer – Finally Hints of a Breakthrough Published 05 January 2021 Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway has been strongly linked with prostate cancer progression and metastatic potential. 1 Loss of the inhibitory phosphatase, PTEN, leading to hyperactivation of PI3K/AKT/mTOR oncogenic signaling, occurs in 40-50% of metastatic castration-resistant prostate cancer. 1,2 Not surprising is the fact that PTEN loss in patients with metastatic castration-resistant prostate cancer is associated with a worse prognosis and less benefit from androgen receptor (AR) blockade. 3 Likewise, PTEN loss and subsequent Akt activation confer radiation

United statesFred hutchinson cancer research centerUniversity of washingtonYunfeng liShunyou wangEvany shiNicholast ingoliaSeema plaisierVivekk aroraRatnab rayYu chenAshkan morimHoujian caiWilliame friedrichsBretts carverSarat chandarlapaty